Alzinova AB
Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, call… Read more
Alzinova AB (ALZ) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.039x
Based on the latest financial reports, Alzinova AB (ALZ) has a cash flow conversion efficiency ratio of -0.039x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-5.01 Million) by net assets (Skr127.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Alzinova AB - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Alzinova AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Alzinova AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alzinova AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Acco Group Holdings Limited Ordinary Shares
NASDAQ:ACCL
|
-0.123x |
|
BQUE NATLE BELG. O.N.
F:BKB
|
N/A |
|
Tel-Instrument Electronics Corp
OTCQB:TIKK
|
-0.015x |
|
Tadmax Resources Berhad
KLSE:4022
|
-0.086x |
|
Evion Group NL
AU:EVG
|
-0.125x |
|
Xpedra Resources Limited
AU:XPD
|
-0.085x |
|
Logismos Information Systems S.A
AT:LOGISMOS
|
0.026x |
|
FG Financial Group
NASDAQ:FGF
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Alzinova AB (2014–2024)
The table below shows the annual cash flow conversion efficiency of Alzinova AB from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr123.82 Million | Skr-20.27 Million | -0.164x | -22.49% |
| 2023-12-31 | Skr113.86 Million | Skr-15.21 Million | -0.134x | -36.72% |
| 2022-12-31 | Skr105.53 Million | Skr-10.31 Million | -0.098x | +11.95% |
| 2021-12-31 | Skr88.47 Million | Skr-9.82 Million | -0.111x | -70.10% |
| 2020-12-31 | Skr96.02 Million | Skr-6.27 Million | -0.065x | +2.98% |
| 2019-12-31 | Skr59.11 Million | Skr-3.98 Million | -0.067x | -8.08% |
| 2018-12-31 | Skr63.75 Million | Skr-3.97 Million | -0.062x | +14.16% |
| 2017-12-31 | Skr29.39 Million | Skr-2.13 Million | -0.072x | +16.33% |
| 2016-12-31 | Skr31.90 Million | Skr-2.76 Million | -0.087x | +44.29% |
| 2015-12-31 | Skr20.63 Million | Skr-3.21 Million | -0.156x | +66.23% |
| 2014-12-31 | Skr1.55 Million | Skr-715.19K | -0.461x | -- |